9.1 Anti-VEGF Agents & Neovascular Retinal Diseases

Anti-VEGF Agents and Safe Treatment Support

Vascular endothelial growth factor promotes vascular permeability and new-vessel growth. In the retina, excessive signaling contributes to neovascular AMD, diabetic macular edema and retinopathy, retinal vein occlusion edema, myopic neovascularization, and other clinician-defined conditions. Blocking VEGF can reduce leakage or neovascular activity, but it does not erase underlying disease or guarantee a visual result.

Agents and targets

• Bevacizumab is a full-length antibody used intravitreally off label when prepared through an authorized compounding or pharmacy pathway.
• Ranibizumab is an antibody fragment targeting VEGF-A with ophthalmic indications and product-specific formulations.
• Aflibercept is a fusion protein that binds VEGF-family ligands; labeled doses and formulations must not be assumed interchangeable.
• Brolucizumab is a small antibody fragment with important intraocular inflammation and retinal vascular-occlusion warnings.
• Faricimab is bispecific for VEGF-A and angiopoietin-2.

Names, biosimilars, strengths, prefilled-syringe formats, and indications change. Verify the exact generic, brand or biosimilar, concentration, dose, eye, route, lot, expiration, order, and label. The technician does not substitute one agent or strength because another product is unavailable.

Treatment strategies

A fixed plan gives treatment at predefined intervals supported for a product and condition. PRN or as-needed treatment uses scheduled monitoring with treatment according to clinician-defined activity criteria. Treat and extend changes intervals according to anatomy, vision, history, tolerance, disease, and product. There is no universal extension step or maximum interval. Reliable acuity, OCT, examination support, and history help the clinician decide; the technician does not label a scan active or independently schedule the next injection.

History and monitoring

Record diagnosis as documented, treated eye, prior agent and dates, response, missed visits, prior inflammation or infection, pressure events, vascular-occlusion history, pregnancy when relevant, systemic medications, allergies or reactions, and new symptoms. Prior tolerance does not eliminate future risk.

Imaging follow-up should reproduce device, scan pattern, centering, registration, signal, and segmentation when possible. Preserve artifacts and note changes in acquisition. Fluid, hemorrhage, pigment epithelial detachment, atrophy, fibrosis, or vision change has a differential diagnosis and requires clinician interpretation.

Storage, compounding, and preparation

Biologic products are sensitive to time, temperature, light, packaging, and handling. Use the current product label and pharmacy policy. Monitor the approved storage system, preserve lot and expiration or beyond-use traceability, and quarantine a temperature excursion, suspected freezing, damaged package, recall, particles, discoloration, or uncertain history. Do not shake, warm, discard, or return a product to use based on a rule borrowed from a different agent.

Compounded bevacizumab and other repackaged products require an authorized source, intact tamper-evident packaging, labeled strength and volume, storage and beyond-use information, and the facility's sterility and recall controls. A technician does not divide a vial, choose a filter or needle, or alter a syringe unless specifically trained, delegated, and supported by current pharmacy and product procedures.

Adverse events and escalation

After an injection, increasing pain, redness, photophobia, discharge, marked vision decline, hypopyon, or progressive inflammation raises concern for infection or severe inflammation and needs prompt evaluation. New scotoma, field change, vascular whitening, vasculitis concern, or severe inflammation after an agent with a retinal-vascular warning also requires immediate clinician review. Surface irritation or subconjunctival hemorrhage can occur, but a technician should not use a normal-effects list to dismiss a worsening symptom.

Systemic symptoms such as facial swelling, breathing difficulty, hypotension, chest pain, or focal neurologic change activate the appropriate emergency pathway. Product complaint, contamination, cluster, or device failure information—including lot, syringe, storage log, and timeline—is preserved for safety reporting.

Scope

The CRT verifies, documents, acquires ordered measurements, protects the medication pathway, and escalates. The licensed clinician and pharmacy system select agent, dose, regimen, compounding method, and disposition. A safe answer to a product or interval question is to preserve the facts and obtain the current authorized determination.

Medication time-out and closed-loop handoff

Before preparation or administration, reconcile two identifiers, eye, agent, strength, dose, route, order, consent status, allergies or prior reaction, lot and expiration when required, and the treating clinician's plan. The syringe label, order, schedule, consent, patient statement, and time-out must agree. A mismatch is quarantined and resolved; it is not fixed by relabeling from memory.

After the procedure, document the product and eye, time, personnel, required checks, patient tolerance, education, and disposition. Use the approved follow-up and emergency contact instructions. If the patient cannot return as planned, route the barrier through the clinician-approved urgency process instead of choosing a substitute interval.